FABP1

Summary

FABP1 (fatty acid binding protein 1, HGNC:3555) is a protein-coding gene on chromosome 2p11.2, encoding Fatty acid-binding protein, liver (P07148). Plays a role in lipoprotein-mediated cholesterol uptake in hepatocytes.

This gene encodes the fatty acid binding protein found in liver. Fatty acid binding proteins are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and other hydrophobic ligands. This protein and FABP6 (the ileal fatty acid binding protein) are also able to bind bile acids. It is thought that FABPs roles include fatty acid uptake, transport, and metabolism.

Source: NCBI Gene 2168 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 21 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001443

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3555
Approved symbol	FABP1
Name	fatty acid binding protein 1
Location	2p11.2
Locus type	gene with protein product
Status	Approved
Aliases	L-FABP
Ensembl gene	ENSG00000163586
Ensembl biotype	protein_coding
OMIM	134650
Entrez	2168

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000295834, ENST00000393750, ENST00000472846, ENST00000495375, ENST00000877228, ENST00000877229, ENST00000877230, ENST00000877231, ENST00000945195, ENST00000945196

RefSeq mRNA: 1 — MANE Select: NM_001443 NM_001443

CCDS: CCDS2001

Canonical transcript exons

ENST00000295834 — 4 exons

Exon	Start	End
ENSE00001076278	88122982	88123104
ENSE00001076280	88124494	88124586
ENSE00001876850	88127951	88128062
ENSE00003514397	88126176	88126348

Expression profiles

Bgee: expression breadth ubiquitous, 168 present calls, max score 99.99.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 32.1513 / max 7588.9007, expressed in 157 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
29593	32.1513	157

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	99.99	gold quality
colonic mucosa	UBERON:0000317	99.97	gold quality
jejunal mucosa	UBERON:0000399	99.97	gold quality
mucosa of sigmoid colon	UBERON:0004993	99.96	gold quality
ileal mucosa	UBERON:0000331	99.95	gold quality
rectum	UBERON:0001052	99.94	gold quality
right lobe of liver	UBERON:0001114	99.91	gold quality
liver	UBERON:0002107	99.73	gold quality
caecum	UBERON:0001153	97.85	gold quality
adult mammalian kidney	UBERON:0000082	97.82	gold quality
vermiform appendix	UBERON:0001154	97.60	gold quality
small intestine Peyer’s patch	UBERON:0003454	97.59	gold quality
small intestine	UBERON:0002108	96.91	gold quality
transverse colon	UBERON:0001157	96.64	gold quality
duodenum	UBERON:0002114	96.25	gold quality
adult organism	UBERON:0007023	94.15	gold quality
intestine	UBERON:0000160	92.97	gold quality
large intestine	UBERON:0000059	91.64	gold quality
colon	UBERON:0001155	91.26	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.65	gold quality
kidney	UBERON:0002113	88.71	gold quality
kidney epithelium	UBERON:0004819	87.43	gold quality
nephron tubule	UBERON:0001231	87.36	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.35	gold quality
colonic epithelium	UBERON:0000397	86.54	gold quality
renal glomerulus	UBERON:0000074	83.95	gold quality
sigmoid colon	UBERON:0001159	83.30	gold quality
metanephric glomerulus	UBERON:0004736	83.17	gold quality
jejunum	UBERON:0002115	82.36	gold quality
cortex of kidney	UBERON:0001225	79.95	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 11.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	22574.10
E-MTAB-8410	yes	21299.01
E-MTAB-7407	yes	13504.53
E-CURD-46	yes	8972.04
E-MTAB-10553	yes	8892.58
E-CURD-122	yes	6737.35
E-CURD-88	yes	6219.04
E-HCAD-9	yes	5206.67
E-MTAB-9906	yes	3188.21
E-ANND-5	yes	805.58
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA, FOXA1, GATA4, GATA5, GATA6, HNF1A, HNF4A, PDX1, PPARA, PPARG, PPARGC1B, RXRA, TFAP2A

Literature-anchored findings (GeneRIF, showing 40)

• evidence that FABP is a target for tamoxifen and that target proteins are implicated in cell lipid metabolism (PMID:12121132)
• besides I-FABP, also L-FABP is a useful plasma marker for the detection of intestinal injury, especially in patients undergoing intestinal surgery (PMID:14563446)
• L-FABP has a significant role in oxidative stress (PMID:16175609)
• Urinary L-FABP levels appear to be associated with the progression of diabetic nephropathy, and NK 104 may be effective in ameliorating tubulointerstitial damage in early diabetic nephropathy. (PMID:16249547)
• EPO supplementation may ameliorate renal tubular damage, in part, due to a reduction of oxidative stress in CRF patients with anemia. (PMID:16772708)
• Renal L-FABP may reduce the oxidative stress in the unilateral ureteral obstruction model, ameliorating tubulointerstitial damage. (PMID:17003471)
• L-FABP may play a key role in the progress of invasiveness and metastasis in human breast cancer. (PMID:17428383)
• there is a functional relevance of the FABP1 T94A SNP in hepatic fatty acid and lipid metabolism in humans (PMID:17485234)
• These results have demonstrated that C. trachomatis can productively infect liver cells and utilize FABP-transported long-chain fatty acids for its own biosynthesis. (PMID:17526850)
• Intestinal L-FABP expression was investigated by immuno-histochemistry, western blot, ELISA and Northern blot analysis (PMID:17605029)
• The Ala/Ala(94)-mutation contributed significantly to reduced glycogenolysis and less severe hyperglycemia in lipid-exposed humans and was further associated with reduced body weight in a large cohort. (PMID:17698986)
• Hypoxia enhances the expression of FABP1 in term human trophoblasts, suggesting that fatty acid binding proteins support fat accumulation in the hypoxic placenta. (PMID:17826730)
• Urinary L-FABP levels represent a sensitive and predictive early biomarker of acute kidney injury after cardiac surgery. (PMID:18094680)
• Data show that genotypes for the A–>G (Thr94Ala) polymorphism (rs2241883) of FABP1 was associated (P<0.05) with the prevalence of atherothrombotic cerebral infarction. (PMID:18506375)
• The results suggest that urinary L-FABP levels are significantly increased in patients with septic shock and that PMX-F treatment is effective in reducing these levels. (PMID:18838948)
• Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. (Review) (PMID:19019918)
• study demonstrated the direct, albeit weak, interaction between MES buffer (2-(N-morpholino)ethanesulfonic acid) & liver fatty acid binding protein; finding of buffer-induced changes in protein dynamics offers a clue to how hLFABP accommodates its ligands (PMID:19217864)
• paradoxically underexpressed in nonalcoholic steatohepatitis (PMID:19330863)
• renal expression and urinary excretion of hL-FABP significantly reflected the severity of tubulointerstitial damage in FA-induced nephropathy (PMID:19435794)
• Studies indicate that the members of the FABP family present in mammals that appear to be more closely related to the L-BABPs are the liver FABPs and the ileal BABPs. (PMID:19441025)
• two FABPs display differences in localization, regulation and developmental pattern. (PMID:19499240)
• While B-FABP is over expressed in renal cell carcinoma in comparison to normal renal tissues L-FABP appears to be reduced in tumor tissue (PMID:19622156)
• High levels of the tubular inflammation marker u-LFABP predict the initiation and progression to diabetic nephropathy and all-cause mortality, independent of urinary albumin excretion rate and other established risk factors. (PMID:20185732)
• the slow dynamics of human liver fatty acid binding protein (hLFABP) that was shown previously to be highly flexible on millisecond timescales was quantitatively characterized in detail (PMID:20550918)
• The serum level of I-FABP can be used for assessing the gut dysfunction and disease severity of acute pancreatitis. (PMID:20575163)
• the T94A mutant of L-FABP lowered free fatty acid uptake but had no effect on FFA efflux (PMID:20721681)
• Our study suggests that L-FABP is a useful biomarker for early detection of acute kidney injury. (PMID:21153750)
• Renal hL-FABP reduced the oxidative stress in aristolochic acid-induced nephrotoxicity and attenuated tubulointerstitial damage. (PMID:21356355)
• Review: summarizes the findings on the pathophysiological roles and dynamics of renal human L-FABP in the recent experimental studies performed in a transgenic mouse model. (PMID:21504508)
• liver fatty acid-binding protein (LFABP) in apo, holo, and intermediate states of palmitic acid engagement;Apo-LFABP undergoes structural remodeling, where the first palmitate ingress creates the atomic environment for placement of the second palmitate. (PMID:21757748)
• Data show that IL-FABP mRNA was over-expressed in renal tumour tissue. (PMID:21767383)
• FABP1 gene is highly transcribed in liver-derived cells, and regulated predominantly by liver-enriched transcription factors HNF3B and CEBPA. (PMID:21856370)
• in kidney allograft recipients, L-FABP may be a potential early marker for impaired kidney function/injury (PMID:21996226)
• Common variants of the liver fatty acid binding protein genes 1-4 influence the risk of type 2 diabetes and insulin resistance in Spanish population (PMID:22396741)
• The present study suggests that genetic variations within FABP1 influence susceptibility to non-alcohol fatty liver disease. (PMID:22465531)
• Studies indicate the most studied biomarkers for acute kidney injury are neutrophil gelatinase-associated lipocalin-2, kidney injury molecule-1, IL-18, cystatin C, N-acetyl-beta-D-glucosaminidase, liver fatty-acid binding protein, and heat shock protein 72. (PMID:22515481)
• Baicalin was able to enhance both L-FABP expression and activity of intracellular SOD and GSH, and therefore protected hepatocytes from oxidative stress. (PMID:22525507)
• PDX1 repression of FABP1, LCT, and SI suggests a role for PDX1 in patterning anterior intestinal development. (PMID:22640736)
• Serum FABP1 correlates positively with obesity and insulin resistance in Chinese young adults. (PMID:23144966)
• Urinary L-FABP and NGAL increased at an early stage after cardiac surgery. The combination of the two biomarkers enhanced the accuracy of the early detection of postoperative acute kidney injury after cardiac surgery before a rise in serum creatinine. (PMID:23167703)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	fabp1a	ENSDARG00000019357
danio_rerio	fabp1b.1	ENSDARG00000059227
danio_rerio	fabp1b.2	ENSDARG00000103398
mus_musculus	Fabp1	ENSMUSG00000054422
rattus_norvegicus	Fabp1	ENSRNOG00000006675
caenorhabditis_elegans		WBGENE00002259
caenorhabditis_elegans		WBGENE00002260

Paralogs (15): RBP2 (ENSG00000114113), RBP1 (ENSG00000114115), FABP3 (ENSG00000121769), RBP5 (ENSG00000139194), CRABP2 (ENSG00000143320), FABP2 (ENSG00000145384), PMP2 (ENSG00000147588), RBP7 (ENSG00000162444), FABP7 (ENSG00000164434), FABP5 (ENSG00000164687), CRABP1 (ENSG00000166426), FABP6 (ENSG00000170231), FABP4 (ENSG00000170323), FABP12 (ENSG00000197416), FABP9 (ENSG00000205186)

Protein

Protein identifiers

Fatty acid-binding protein, liver — P07148 (reviewed: P07148)

Alternative names: Fatty acid-binding protein 1, Liver-type fatty acid-binding protein

All UniProt accessions (3): P07148, A8MW49, Q6FGL7

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in lipoprotein-mediated cholesterol uptake in hepatocytes. Binds cholesterol. Binds free fatty acids and their coenzyme A derivatives, bilirubin, and some other small molecules in the cytoplasm. May be involved in intracellular lipid transport.

Subcellular location. Cytoplasm.

Domain organisation. Forms a beta-barrel structure that accommodates hydrophobic ligands in its interior.

Similarity. Belongs to the calycin superfamily. Fatty-acid binding protein (FABP) family.

RefSeq proteins (1): NP_001434* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000463	Fatty_acid-bd	Domain
IPR012674	Calycin	Homologous_superfamily
IPR031259	ILBP	Family

Pfam: PF14651

UniProt features (30 total): modified residue 13, strand 12, sequence variant 2, helix 2, chain 1

Structure

Experimental structures (PDB)

37 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
7FXO	X-RAY DIFFRACTION	1.3
3VG7	X-RAY DIFFRACTION	1.44
7DZK	X-RAY DIFFRACTION	1.54
3B2H	X-RAY DIFFRACTION	1.55
3STK	X-RAY DIFFRACTION	1.55
7DZE	X-RAY DIFFRACTION	1.55
7DZG	X-RAY DIFFRACTION	1.6
7DZJ	X-RAY DIFFRACTION	1.63
7DZL	X-RAY DIFFRACTION	1.64
7G0W	X-RAY DIFFRACTION	1.64
7DZH	X-RAY DIFFRACTION	1.65
7DZI	X-RAY DIFFRACTION	1.65
7G1X	X-RAY DIFFRACTION	1.65
7DZF	X-RAY DIFFRACTION	1.7
3B2K	X-RAY DIFFRACTION	1.73
3B2I	X-RAY DIFFRACTION	1.86
7FYA	X-RAY DIFFRACTION	1.88
3B2J	X-RAY DIFFRACTION	2
3VG5	X-RAY DIFFRACTION	2
3STM	X-RAY DIFFRACTION	2.22
3VG3	X-RAY DIFFRACTION	2.22
3VG6	X-RAY DIFFRACTION	2.22
7FY8	X-RAY DIFFRACTION	2.23
3B2L	X-RAY DIFFRACTION	2.25
3VG2	X-RAY DIFFRACTION	2.4
2F73	X-RAY DIFFRACTION	2.5
3VG4	X-RAY DIFFRACTION	2.5
6MP4	X-RAY DIFFRACTION	2.5
3STN	X-RAY DIFFRACTION	2.6
7G00	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P07148-F1	95.25	0.90

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (13): 1, 78, 90, 100, 121, 11, 31, 36, 39, 46, 51, 56, 57

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-163560	Triglyceride catabolism
R-HSA-189483	Heme degradation
R-HSA-1989781	PPARA activates gene expression
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-9707564	Cytoprotection by HMOX1

MSigDB gene sets: 333 (showing top): REACTOME_TRIGLYCERIDE_CATABOLISM, GOBP_LIPID_MODIFICATION, GOBP_ACYLGLYCEROL_HOMEOSTASIS, GOBP_DIGESTION, MODULE_92, SHEPARD_BMYB_MORPHOLINO_UP, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOBP_FATTY_ACID_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_TRANSPORT, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_DIPHOSPHATE_METABOLIC_PROCESS, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_ACID_SECRETION, GOBP_BEHAVIOR

GO Biological Process (5): fatty acid transport (GO:0015908), cellular response to hydrogen peroxide (GO:0070301), cellular response to hypoxia (GO:0071456), cellular detoxification (GO:1990748), cellular oxidant detoxification (GO:0098869)

GO Molecular Function (5): chromatin binding (GO:0003682), fatty acid binding (GO:0005504), antioxidant activity (GO:0016209), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (6): nucleus (GO:0005634), nucleoplasm (GO:0005654), peroxisomal matrix (GO:0005782), cytosol (GO:0005829), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Triglyceride metabolism	1
Metabolism of porphyrins	1
Regulation of lipid metabolism by PPARalpha	1
Metabolism of lipids	1
Cellular response to chemical stress	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	3
cellular anatomical structure	3
lipid transport	1
monocarboxylic acid transport	1
cellular response to reactive oxygen species	1
response to hydrogen peroxide	1
response to hypoxia	1
cellular response to stress	1
cellular response to decreased oxygen levels	1
cellular process	1
cellular response to toxic substance	1
detoxification	1
cellular detoxification	1
lipid binding	1
monocarboxylic acid binding	1
molecular_function	1
cellular oxidant detoxification	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
peroxisome	1
microbody lumen	1
cytoplasm	1
extracellular vesicle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1657 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FABP1	GOT2	P00505	957
FABP1	FABP2	P12104	950
FABP1	FABP3	P05413	927
FABP1	PPARA	Q07869	913
FABP1	CD36	P16671	881
FABP1	SCARB1	Q8WTV0	873
FABP1	HAVCR1	Q96D42	872
FABP1	SCARB2	Q14108	863
FABP1	FABP4	P15090	816
FABP1	LCN2	P30150	814
FABP1	CST3	P01034	771
FABP1	APOB	P04114	734
FABP1	CPT1A	P50416	677
FABP1	OGA	O60502	667
FABP1	IGFBP7	Q16270	644

IntAct

15 interactions, top by confidence:

A	B	Type	Score
FABP1	FLNA	psi-mi:“MI:0915”(physical association)	0.560
FLNA	FABP1	psi-mi:“MI:0915”(physical association)	0.560
EPHA4	FABP1	psi-mi:“MI:0915”(physical association)	0.560
FABP1	GNPNAT1	psi-mi:“MI:0915”(physical association)	0.560
EPHA4	FABP1	psi-mi:“MI:0914”(association)	0.560
NME4	NRDC	psi-mi:“MI:0914”(association)	0.350
ADCK5	AKR1B10	psi-mi:“MI:0914”(association)	0.350
FABP1	NME2P1	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
FABP1	GRB2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (19): FLNA (Two-hybrid), FLNA (Two-hybrid), FABP1 (Affinity Capture-MS), GNPNAT1 (Affinity Capture-MS), FABP1 (Two-hybrid), FABP1 (Two-hybrid), NME2P1 (Affinity Capture-MS), GNPNAT1 (Affinity Capture-MS), FABP1 (Affinity Capture-MS), FABP1 (Affinity Capture-MS), FABP1 (Affinity Capture-MS), FABP1 (Affinity Capture-MS), FABP1 (Affinity Capture-MS), DERL1 (Affinity Capture-Western), FABP1 (Affinity Capture-Western)

ESM2 similar proteins: A6NFH5, O01812, O02323, O42494, O45035, P02692, P02693, P07148, P0C241, P0DM59, P10289, P12104, P12710, P29498, P31416, P31417, P41496, P41509, P49924, P50119, P51161, P51162, P55050, P80020, P80226, P80425, P80856, P81399, P81400, P81653, P82289, P83409, Q02970, Q0Z7S8, Q17284, Q1AMT3, Q3T0Z2, Q45KW7, Q4VBT1, Q56JX9

Diamond homologs: A0A0K0MJ13, A0A0K0MJN3, A6NFH5, A6YLM6, A8MUU1, B7SUM8, C4N147, O01812, O01814, O02323, O02324, O02772, O08716, O13008, O15540, O42386, O45035, O76821, O97788, P02689, P02690, P02691, P02694, P02696, P04117, P05413, P06768, P07148, P07483, P09455, P0C6G6, P10790, P11404, P12710, P15090, P22935, P24526, P29373, P29498, P29762

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
FABP1	“up-regulates quantity”	“Fatty acid”	relocalization

Disease & clinical

Clinical variants and AI predictions

ClinVar

21 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	18
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

426 predictions. Top by Δscore:

Variant	Effect	Δscore
2:88124492:A:AC	donor_gain	1.0000
2:88124493:C:CC	donor_gain	1.0000
2:88124493:CA:C	donor_gain	1.0000
2:88124583:CTGT:C	acceptor_gain	1.0000
2:88124585:GTC:G	acceptor_loss	1.0000
2:88124586:TC:T	acceptor_loss	1.0000
2:88124587:C:CA	acceptor_loss	1.0000
2:88124587:C:CC	acceptor_gain	1.0000
2:88124588:T:A	acceptor_loss	1.0000
2:88126246:TTGG:T	donor_gain	1.0000
2:88127949:A:AC	donor_gain	1.0000
2:88127950:C:CC	donor_gain	1.0000
2:88124493:CATT:C	donor_gain	0.9900
2:88124493:CATTG:C	donor_gain	0.9900
2:88124584:TGT:T	acceptor_gain	0.9900
2:88124585:GT:G	acceptor_gain	0.9900
2:88127946:CT:C	donor_loss	0.9900
2:88127947:TCA:T	donor_loss	0.9900
2:88127948:CACC:C	donor_loss	0.9900
2:88127950:C:A	donor_loss	0.9900
2:88124488:ACT:A	donor_loss	0.9800
2:88124489:CT:C	donor_loss	0.9800
2:88124490:T:TC	donor_loss	0.9800
2:88124491:TAC:T	donor_loss	0.9800
2:88124492:ACATT:A	donor_loss	0.9800
2:88124493:CAT:C	donor_gain	0.9800
2:88126173:TACC:T	donor_loss	0.9800
2:88126175:C:CT	donor_loss	0.9800
2:88126240:A:AC	donor_gain	0.9800
2:88123150:T:TC	acceptor_gain	0.9700

AlphaMissense

854 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:88127999:A:C	Y7D	0.988
2:88127998:T:G	Y7S	0.985
2:88123066:G:C	S124R	0.971
2:88123066:G:T	S124R	0.971
2:88123068:T:G	S124R	0.971
2:88124555:A:G	L91P	0.971
2:88126227:G:C	F63L	0.967
2:88126227:G:T	F63L	0.967
2:88126229:A:G	F63L	0.967
2:88126228:A:G	F63S	0.966
2:88127999:A:T	Y7N	0.965
2:88124579:A:T	V83D	0.964
2:88127964:G:C	F18L	0.964
2:88127964:G:T	F18L	0.964
2:88127966:A:G	F18L	0.964
2:88128004:C:T	G5D	0.961
2:88124529:A:G	S100P	0.960
2:88127999:A:G	Y7H	0.957
2:88123060:T:A	R126S	0.953
2:88123060:T:G	R126S	0.953
2:88126273:A:G	F48S	0.949
2:88127965:A:G	F18S	0.949
2:88128004:C:A	G5V	0.943
2:88127998:T:C	Y7C	0.940
2:88128009:G:C	F3L	0.940
2:88128009:G:T	F3L	0.940
2:88128011:A:G	F3L	0.940
2:88128010:A:G	F3S	0.938
2:88124555:A:C	L91R	0.933
2:88127957:C:G	A21P	0.932

dbSNP variants (sampled 300 via entrez): RS1000074723 (2:88124280 T>C,G), RS1000878160 (2:88126006 C>T), RS1001112664 (2:88128486 T>C), RS1001263833 (2:88125177 C>A), RS1002422621 (2:88125572 G>A), RS1002776849 (2:88126154 A>T), RS1003372885 (2:88127398 T>C), RS1003881703 (2:88123854 A>T), RS1004781618 (2:88128291 T>C), RS1004896092 (2:88128030 G>A,C), RS1005720647 (2:88123474 A>G), RS1005829798 (2:88129644 A>C), RS1005901551 (2:88129359 A>G), RS1006018861 (2:88123787 C>T), RS1007038459 (2:88127430 A>G)

Disease associations

OMIM: gene MIM:134650 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST003542_178	Night sleep phenotypes	3.000000e-08
GCST006585_585	Blood protein levels	5.000000e-21
GCST007614_37	C-reactive protein levels	5.000000e-10
GCST008469_17	Liver fibrosis in non-alcoholic fatty liver disease	8.000000e-08
GCST90011898_98	Alanine aminotransferase levels	4.000000e-09
GCST90011900_4	Serum alkaline phosphatase levels	3.000000e-17
GCST90013406_280	Liver enzyme levels (alkaline phosphatase)	1.000000e-26

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004458	C-reactive protein measurement
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5421 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 749,198 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL95	TACRINE	4	35,360
CHEMBL8659	OLEIC ACID	2	713,838

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs2241883	Efficacy	4	fenofibrate	Hypertriglyceridemia

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2241883	FABP1	4	-1.50	1	fenofibrate

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Fatty acid-binding proteins

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
fenofibrate	Inhibition	7.62	pKi
fenofibric acid	Inhibition	6.48	pKi
HTS01037	Inhibition	5.09	pKi

Binding affinities (BindingDB)

1 measured of 2 human assays (3 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
3,7,11,15-tetramethylhexadecanoic acid	KI	38 nM

ChEMBL bioactivities

31 potent at pChembl≥5 of 40 total, top 30 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.70	Kd	200	nM	OLEIC ACID
6.05	Kd	900	nM	OLEIC ACID
5.93	IC50	1180	nM	CHEMBL5612524
5.85	IC50	1400	nM	CHEMBL5394417
5.82	IC50	1500	nM	CHEMBL5396259
5.74	IC50	1820	nM	CHEMBL5612235
5.70	Kd	2000	nM	CHEMBL471741
5.68	IC50	2110	nM	CHEMBL5613265
5.61	IC50	2440	nM	CHEMBL5612678
5.58	IC50	2660	nM	CHEMBL5614355
5.57	IC50	2700	nM	CHEMBL5396467
5.57	IC50	2710	nM	CHEMBL247920
5.54	IC50	2900	nM	CHEMBL5420532
5.52	IC50	3020	nM	CHEMBL5613315
5.49	IC50	3240	nM	CHEMBL5613794
5.48	IC50	3300	nM	CHEMBL5429880
5.44	IC50	3600	nM	CHEMBL5420842
5.42	IC50	3800	nM	CHEMBL5419154
5.40	IC50	4000	nM	CHEMBL247920
5.38	IC50	4200	nM	CHEMBL5420029
5.37	IC50	4300	nM	CHEMBL5436041
5.35	IC50	4460	nM	CHEMBL5556772
5.25	IC50	5660	nM	CHEMBL5612128
5.24	IC50	5700	nM	CHEMBL5439051
5.21	IC50	6110	nM	CHEMBL5611914
5.14	IC50	7280	nM	CHEMBL5517962
5.09	Ki	8170	nM	CHEMBL1077990
5.07	IC50	8500	nM	CHEMBL6151098
5.06	IC50	8710	nM	CHEMBL5558673
5.06	IC50	8630	nM	CHEMBL5559644

PubChem BioAssay actives

35 with measured affinity, of 314 total; 30 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
Fenofibrate	1800412: ANS Fluorescence Displacement Assay from Article 10.1021/bi401014k: “The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates.”	ki	0.0150	uM
3,7,11,15-tetramethylhexadecanoic acid	1800412: ANS Fluorescence Displacement Assay from Article 10.1021/bi401014k: “The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates.”	ki	0.0350	uM
(Z)-octadec-9-enoic acid	407370: Binding affinity to L-FABP high binding affinity site by titration calorimetry method	kd	0.2000	uM
Fenofibric Acid	1800412: ANS Fluorescence Displacement Assay from Article 10.1021/bi401014k: “The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates.”	ki	0.2500	uM
3-[2-(4-quinolin-8-ylsulfonylpiperazin-1-yl)sulfonylphenyl]phenol	2126076: Inhibition of human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	1.1800	uM
3-[4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]phenyl]propanoic acid	1987909: Displacement of 8-anilino-1-naphthalene-sulfonic acid from FABP1 (unknown origin) incubated for 3 mins by fluorescence based assay	ic50	1.4000	uM
2-[3-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]phenyl]-2-methylpropanoic acid	1987909: Displacement of 8-anilino-1-naphthalene-sulfonic acid from FABP1 (unknown origin) incubated for 3 mins by fluorescence based assay	ic50	1.5000	uM
4-[2-(4-quinolin-8-ylsulfonylpiperazin-1-yl)sulfonylphenyl]phenol	2126076: Inhibition of human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	1.8200	uM
(8-anilinonaphthalen-1-yl) hydrogen sulfate	407367: Binding affinity to human L-FABP	kd	2.0000	uM
4-[2-(4-quinolin-8-ylsulfonylpiperazin-1-yl)sulfonylphenyl]benzoic acid	2126076: Inhibition of human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	2.1100	uM
8-[4-(quinolin-8-ylsulfonylamino)phenoxy]octanoic acid	2126076: Inhibition of human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	2.4400	uM
4-[2-(4-quinolin-8-ylsulfonylpiperazin-1-yl)sulfonylphenyl]benzonitrile	2126076: Inhibition of human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	2.6600	uM
1-[3-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]phenyl]cyclopropane-1-carboxylic acid	1987909: Displacement of 8-anilino-1-naphthalene-sulfonic acid from FABP1 (unknown origin) incubated for 3 mins by fluorescence based assay	ic50	2.7000	uM
2-[3-[2-(5-ethyl-3,4-diphenylpyrazol-1-yl)phenyl]phenoxy]acetic acid	2126076: Inhibition of human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	2.7100	uM
2-[4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]phenyl]acetic acid	1987909: Displacement of 8-anilino-1-naphthalene-sulfonic acid from FABP1 (unknown origin) incubated for 3 mins by fluorescence based assay	ic50	2.9000	uM
8-[3-(quinolin-8-ylsulfonylamino)phenoxy]octanoic acid	2126076: Inhibition of human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	3.0200	uM
8-[3-[(4-phenylphenyl)sulfonylamino]phenoxy]octanoic acid	2126076: Inhibition of human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	3.2400	uM
3-[3-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]phenyl]propanoic acid	1987909: Displacement of 8-anilino-1-naphthalene-sulfonic acid from FABP1 (unknown origin) incubated for 3 mins by fluorescence based assay	ic50	3.3000	uM
2-[4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]phenoxy]propanoic acid	1987909: Displacement of 8-anilino-1-naphthalene-sulfonic acid from FABP1 (unknown origin) incubated for 3 mins by fluorescence based assay	ic50	3.6000	uM
2-[3-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]phenoxy]acetic acid	1987909: Displacement of 8-anilino-1-naphthalene-sulfonic acid from FABP1 (unknown origin) incubated for 3 mins by fluorescence based assay	ic50	3.8000	uM
2-[4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]phenoxy]acetic acid	1987909: Displacement of 8-anilino-1-naphthalene-sulfonic acid from FABP1 (unknown origin) incubated for 3 mins by fluorescence based assay	ic50	4.2000	uM
2-[4-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]phenyl]acetic acid	1987909: Displacement of 8-anilino-1-naphthalene-sulfonic acid from FABP1 (unknown origin) incubated for 3 mins by fluorescence based assay	ic50	4.3000	uM
3-[3-(cyclopropylmethoxy)phenyl]-5-[(3-phenoxybenzoyl)amino]benzoic acid	2075680: Inhibition of recombinant human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	4.4600	uM
8-[4-[2-(4-fluorophenyl)phenyl]sulfonylpiperazin-1-yl]sulfonylquinoline	2126076: Inhibition of human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	5.6600	uM
2-[4-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]phenoxy]-2-methylpropanoic acid	1987909: Displacement of 8-anilino-1-naphthalene-sulfonic acid from FABP1 (unknown origin) incubated for 3 mins by fluorescence based assay	ic50	5.7000	uM
8-[4-[2-(4-fluoro-2-methylphenyl)phenyl]sulfonylpiperazin-1-yl]sulfonylquinoline	2126076: Inhibition of human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	6.1100	uM
3-(4-tert-butylphenyl)-5-[(3-phenoxybenzoyl)amino]benzoic acid	2075680: Inhibition of recombinant human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	7.2800	uM
(E)-4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid	468322: Displacement of radiolabeled 1-anilinonaphthalene 8-sulfonic acid from LFABP expressed in Escherichia coli BL21 (DE3) by fluorescence spectrophotometry	ki	8.1700	uM
3-[(3-phenoxybenzoyl)amino]-5-(3-propoxyphenyl)benzoic acid	2075680: Inhibition of recombinant human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	8.6300	uM
3-(3-ethoxyphenyl)-5-[(3-phenoxybenzoyl)amino]benzoic acid	2075680: Inhibition of recombinant human FABP1 incubated for 3 mins by fluorescence based analysis	ic50	8.7100	uM

CTD chemical–gene interactions

141 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases mutagenesis, affects methylation, affects cotreatment, affects expression	7
perfluorooctanoic acid	decreases expression, affects cotreatment, increases expression, affects expression	5
Aflatoxin B1	affects expression, decreases expression, decreases methylation	4
Oleic Acid	affects expression, affects cotreatment, increases expression, decreases expression, decreases reaction (+1 more)	4
pirinixic acid	affects binding, increases activity, increases expression	3
perfluorooctane sulfonic acid	affects cotreatment, increases expression, affects expression, decreases expression	3
Acetaminophen	affects cotreatment, decreases expression, increases expression	3
Amitriptyline	increases expression	3
Ketoconazole	increases expression	3
Tetrachlorodibenzodioxin	affects expression, decreases expression, increases expression	3
Valproic Acid	decreases expression	3
Cyclosporine	decreases expression, increases expression	3
lasiocarpine	decreases expression	2
benzo(b)fluoranthene	decreases expression, affects expression, affects cotreatment	2
sodium arsenite	decreases methylation, decreases reaction, decreases expression, increases expression	2
sulindac sulfide	decreases reaction, increases expression, affects reaction	2
perfluorobutyric acid	affects expression, increases expression	2
perfluoro-n-nonanoic acid	affects cotreatment, affects expression, increases expression	2
GW 7647	affects cotreatment, increases expression	2
perfluorohexanesulfonic acid	increases expression, affects cotreatment, affects expression	2
perfluorododecanoic acid	decreases expression	2
Amiodarone	increases expression	2
trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride	increases expression	2
Bezafibrate	affects cotreatment, affects localization, increases expression, decreases expression, decreases reaction	2
Chlorpromazine	increases expression	2
Clozapine	increases expression	2
Flecainide	increases expression	2
Fluoxetine	increases expression	2
Imipramine	increases expression	2
Perhexiline	increases expression	2

ChEMBL screening assays

17 unique, capped per target: 17 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1102423	Binding	Displacement of radiolabeled 1-anilinonaphthalene 8-sulfonic acid from LFABP expressed in Escherichia coli BL21 (DE3) by fluorescence spectrophotometry	Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.